Peak Bio, Inc. (PKBO)
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.
$925.00K
Dr. Stephen LaMond M.B.A., Pharm.D., PharmD MBA
30.00
Palo Alto, CA
Mar 15, 2021
-0.22
$-0.18
0.01
0.08
-4,132.53%
-0.05
-0.06
2.04
0.01
-1,430.76%
-743.96%
Similar stocks (3)
MediciNova, Inc.
MNOV
Champions Oncology, Inc.
CSBR
Anebulo Pharmaceuticals, Inc.
ANEB
Similar stocks (3)
MediciNova, Inc.
MNOV
Champions Oncology, Inc.
CSBR
Anebulo Pharmaceuticals, Inc.
ANEB